Question explored with the scientific record
Conversation so far
- 1 Can I change from truvada to descovy on pep with raltegravir?
- 2 What dosage of descovy
- 3 has descovy been tested for pep?
- 4 but dont descovy and truvada do the same thing?
Answered on this page ↓
but dont descovy and truvada do the same thing?
The short version: no. They share one drug (emtricitabine) and differ in the other, and that difference is the whole point.
Truvada is emtricitabine plus tenofovir disoproxil fumarate (TDF). Descovy is emtricitabine plus tenofovir alafenamide (TAF). Same job, different second drug.
The difference that matters to you is kidney and bone. TAF was designed to deliver the same antiviral punch at a lower dose with less exposure to the rest of the body. In treatment trials, TAF held viral suppression about as well as TDF, roughly 92 in 100 versus 90 in 100 [3], while bone density at the hip fell about 0.7% on TAF versus about 3% on TDF [2][3]. Kidney markers moved less on TAF too [3].
| Truvada | Descovy | |
|---|---|---|
| Second drug | TDF 300 mg | TAF 25 mg |
| Viral suppression | ~90 in 100 [3] | ~92 in 100 [3] |
| Hip bone loss, 48 wk | ~3% [2] | ~0.7% [2] |
| Kidney signal | more creatinine rise [3] | less [3] |
For PEP specifically, the honest gap stands: the only PEP study here used a TAF pill bundled with two other drugs, and it was observational [1]. Nothing here tested Descovy alone as a PEP backbone.
My call: they do the same job, but Descovy is the gentler version on kidney and bone, and that advantage is proven in treatment, not in PEP. Confidence: high that they differ; moderate that the difference favors Descovy for a short PEP course.
Sources used 3
-
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
This retrospective observational study evaluates the completion rates and safety profiles of doravirine-lamivudine-tenofovir disoproxil fumarate (DOR/3TC/TDF) compared to elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide (EVG/c/FTC/TAF) as post-exposure prophylaxis (PE…
DOI: 10.1186/s12879-023-08544-x -
Emtricitabine + tenofovir alafenamide for the treatment of HIV
This study reviews the efficacy and safety of tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF) in HIV treatment, highlighting TAF's improved safety profile regarding renal and bone health.
DOI: 10.1080/14656566.2017.1288720 -
The role of tenofovir alafenamide in future HIV management
A comprehensive review of tenofovir alafenamide (TAF) and its potential to improve future HIV management by delivering potent antiviral efficacy at lower doses with reduced renal and bone toxicity compared with tenofovir disoproxil fumarate (TDF), across treatment-naïve and viro…
DOI: 10.1111/HIV.12401